Iterative Scopes expands IBD offering with acquisitions  


Precision medicine technologies company Iterative Scopes has acquired two clinical trial optimisation companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD). 

The company has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision) in an effort to bolster its efforts in IBD clinical research. Iterative Scopes will use the acquisitions to strengthen its knowledge of the end-to-end research process with a focus on provider viewpoints and pain points.  

Iterative Scopes hopes that the acquisitions will help improve patient outcomes by accelerating the development of improved treatment options.  

The President and CEO of both companies, Chris Fourment, MD has joined Iterative Scopes as SVP of Clinical Strategy. 

CRSG/Precision works with a network of clinical research sites and community gastroenterologists nationwide to set up and optimise clinical trials for IBD drug development. Through their ties to the provider community, Iterative Scopes hopes it can help improve its AI Recruitment service which is designed to help patients, providers and pharmaceutical partners through a combination of AI-driven algorithms and computer vision advances. 

Official comments  

Iterative Scopes founder and CEO Dr Jonathan Ng, said: “With the addition of CRSG and Precision, Iterative Scopes has the opportunity to work more closely with different types of clinical trial sites and providers and to gain sophisticated insights about their needs and pain points, with the goal of refining our ground-breaking AI Recruitment service. Community sites face different challenges and opportunities than other types of providers, and these acquisitions help us create an intimate, holistic and fulsome knowledge of all stakeholders involved in the research process. While I have known Chris for some time now, we are thrilled to finally have him aboard our team, bringing his globally renowned expertise in IBD research to Iterative Scopes.” 

“I am excited to join Iterative Scopes to help the organisation further harness machine learning and computer vision to aid physicians as they work to improve clinical outcomes for IBD patients earlier and with greater success,” said Dr Chris Fourment. “The current clinical trial process for IBD drug development has patient recruitment and clinical team workflow challenges. Iterative Scopes is employing cutting-edge computational algorithms and support services that have the potential to resolve these challenges.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free